DE2148391A1 - Arzneimittel mit verlängerter Wirk stoffabgabe - Google Patents
Arzneimittel mit verlängerter Wirk stoffabgabeInfo
- Publication number
- DE2148391A1 DE2148391A1 DE19712148391 DE2148391A DE2148391A1 DE 2148391 A1 DE2148391 A1 DE 2148391A1 DE 19712148391 DE19712148391 DE 19712148391 DE 2148391 A DE2148391 A DE 2148391A DE 2148391 A1 DE2148391 A1 DE 2148391A1
- Authority
- DE
- Germany
- Prior art keywords
- binder
- drug
- calcium
- medicament
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 47
- 229940079593 drug Drugs 0.000 title claims description 30
- 239000013543 active substance Substances 0.000 title description 3
- 230000002035 prolonged effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 27
- 239000011230 binding agent Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 15
- 229910052791 calcium Inorganic materials 0.000 claims description 15
- 159000000003 magnesium salts Chemical class 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 8
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 4
- -1 dicarboxylic acid ester Chemical class 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 claims description 2
- 229960000445 ethisterone Drugs 0.000 claims description 2
- 239000012439 solid excipient Substances 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 42
- 239000012530 fluid Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940119751 dextroamphetamine sulfate Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- BNHGKKNINBGEQL-UHFFFAOYSA-M sodium;5-ethyl-5-(3-methylbutyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CC(C)CCC1(CC)C(=O)NC(=O)[N-]C1=O BNHGKKNINBGEQL-UHFFFAOYSA-M 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- JXDJNYNWLLLKCG-UHFFFAOYSA-N 5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione Chemical compound CC(C)CCC1C(=O)NC(=O)NC1=O JXDJNYNWLLLKCG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940063002 magnesium palmitate Drugs 0.000 description 1
- ABSWXCXMXIZDSN-UHFFFAOYSA-L magnesium;hexadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O ABSWXCXMXIZDSN-UHFFFAOYSA-L 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4608670A GB1359643A (en) | 1970-09-28 | 1970-09-28 | Controlled release medicament |
| US8254870A | 1970-10-19 | 1970-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2148391A1 true DE2148391A1 (de) | 1972-04-06 |
Family
ID=26265730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712148391 Pending DE2148391A1 (de) | 1970-09-28 | 1971-09-28 | Arzneimittel mit verlängerter Wirk stoffabgabe |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE773113A (OSRAM) |
| CA (1) | CA952431A (OSRAM) |
| DE (1) | DE2148391A1 (OSRAM) |
| FR (1) | FR2108032A1 (OSRAM) |
| NL (1) | NL7113307A (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2336218A1 (de) * | 1973-07-17 | 1975-02-06 | Byk Gulden Lomberg Chem Fab | Neue orale arzneiform und verfahren zu ihrer herstellung |
| JPS55129219A (en) * | 1979-03-29 | 1980-10-06 | Asahi Chem Ind Co Ltd | Slow-releasing preparation |
| EP0069259A3 (en) * | 1981-07-07 | 1983-06-15 | Dr. Karl Thomae Gmbh | Prolonged-action form of bromohexine, and process for its preparation |
| EP0194838A3 (en) * | 1985-03-08 | 1988-02-03 | Yamanouchi Pharmaceutical Co. Ltd. | Controlled-release pharmaceutical formulation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| TWI291871B (en) | 2000-11-01 | 2008-01-01 | Cognition Pharmaceuticals Llc | Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning |
| US20030232890A1 (en) | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB793808A (en) * | 1954-07-22 | 1958-04-23 | Frank Mario Bardani | Sustained action pill |
| US3577514A (en) * | 1968-06-10 | 1971-05-04 | Pfizer | Sustained release pharmaceutical tablets |
-
1971
- 1971-09-27 BE BE773113A patent/BE773113A/xx unknown
- 1971-09-27 CA CA123,786A patent/CA952431A/en not_active Expired
- 1971-09-28 FR FR7134810A patent/FR2108032A1/fr active Granted
- 1971-09-28 NL NL7113307A patent/NL7113307A/xx unknown
- 1971-09-28 DE DE19712148391 patent/DE2148391A1/de active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2336218A1 (de) * | 1973-07-17 | 1975-02-06 | Byk Gulden Lomberg Chem Fab | Neue orale arzneiform und verfahren zu ihrer herstellung |
| JPS55129219A (en) * | 1979-03-29 | 1980-10-06 | Asahi Chem Ind Co Ltd | Slow-releasing preparation |
| EP0069259A3 (en) * | 1981-07-07 | 1983-06-15 | Dr. Karl Thomae Gmbh | Prolonged-action form of bromohexine, and process for its preparation |
| EP0194838A3 (en) * | 1985-03-08 | 1988-02-03 | Yamanouchi Pharmaceutical Co. Ltd. | Controlled-release pharmaceutical formulation |
| EP0533297A1 (en) * | 1985-03-08 | 1993-03-24 | Yamanouchi Pharmaceutical Co. Ltd. | Controlled-release pharmaceutical formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| NL7113307A (OSRAM) | 1972-03-30 |
| CA952431A (en) | 1974-08-06 |
| BE773113A (fr) | 1972-01-17 |
| FR2108032A1 (en) | 1972-05-12 |
| FR2108032B1 (OSRAM) | 1975-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2224534C3 (de) | Pharmazeutisches Präparat mit langsamer Wirkstoffabgabe | |
| EP0272265B1 (de) | Zerfallstablette und verfahren zu ihrer herstellung | |
| DE2433285C2 (de) | Mikrokapseln enthaltende Arzneimittel in Form einer Mehrschichttablette und Verfahren zu ihrer Herstellung | |
| DE3811114C2 (de) | Zweischichtige Dosierungsform zur Abgabe eines Wirkstoffs | |
| DE68916983T2 (de) | Verfahren zur Herstellung eines pharmazeutischen Granulats. | |
| DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
| DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
| DE1258548C2 (de) | Verfahren zur Herstellung von Arzneimitteltabletten unter Verwendung von Kunstharzen als die Wirkstoffabgabe verzoegernde Einbettungsmassen | |
| EP0122574B2 (de) | Teilbare Tablette mit verzögerter Wirkstofffreigabe und Verfahren zu deren Herstellung | |
| DE1292783B (de) | Verfahren zum Herstellen einer Tablette mit Depotwirkung | |
| DE3228999C2 (de) | Pharmazeutische Zusammensetzungen mit verzögerter Wirkstofffreigabe | |
| DE1467906A1 (de) | Verfahren zur Herstellung von sich langsam loesenden Tabletten | |
| DE2323686A1 (de) | Arzneimittelzubereitungsform mit langzeitwirkung und verfahren zu ihrer herstellung | |
| DE3524572A1 (de) | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung | |
| DE4031881A1 (de) | Loesungsmittelfreie, oral zu verabreichende pharmazeutische zubereitung mit verzoegerter wirkstoffreisetzung und verfahren zu deren herstellung | |
| AT399277B (de) | Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung | |
| DE2706660A1 (de) | Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung | |
| DE2128461A1 (de) | Pharmazeutisches Präparat | |
| EP2863891B1 (de) | Arzneiform zur verlängerten freisetzung von wirkstoffen | |
| DE68905613T2 (de) | Pharmazeutische Zubereitung. | |
| DE69008107T2 (de) | Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs. | |
| DE1088192B (de) | Verfahren zur Herstellung von tablettierbaren oder direkt verwendbaren Arzneimittelgranulaten mit einstellbaren Freigabeeigenschaften | |
| EP0208144B1 (de) | Ambroxol oder bromhexin enthaltendes arzneimittelgranulat | |
| DE2148391A1 (de) | Arzneimittel mit verlängerter Wirk stoffabgabe | |
| DE3424975A1 (de) | Pharmazeutisches mittel mit einem fluessigen, hydrophilen gleitmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHA | Expiration of time for request for examination |